On September 1, 2022 Photocure ASA (OSE: PHO), the Bladder Cancer Company, reported the appointment of Dr. Anders Neijber to the position of Chief Medical Officer, Global Medical Affairs and Clinical Development and R&D, effective September 1, 2022 (Press release, PhotoCure, SEP 1, 2022, View Source [SID1234618924]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Neijber is Photocure’s current VP Medical Affairs and Clinical Development and joined the company in August 2021. He brings over 25 years of substantial experience in the Uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional leadership roles, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan, Ferring, and Novartis.

Dr. Neijber is a board-certified urologist, and has held an Assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey.

"In the time that Anders has been with Photocure, he has proven his ability to apply his extensive experience and deep knowledge in the field of Urology, together with his business acumen in leading our Global Medical Affairs strategy" said Dan Schneider, President and Chief Executive Officer of Photocure. "As Photocure continues to grow and expand its global reach, Medical Affairs will have an increasingly important role in navigating the complex health-care environment. Anders will be able to provide a strategic approach beyond addressing the heightened regulatory and compliance regulations, to further build a Global Medical Affairs organization that will have a strong foundation for future scalability and capability globally."

On September 1, 2022 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, reported that members of IMV’s executive management team will be presenting at two investor conferences in September (Press release, IMV, SEP 1, 2022, View Source [SID1234618874]). Please find additional details on the conferences below.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

• H.C. Wainwright 24th Annual Global Investment Conference, New York City
Format: In-person presentation and one-on-one investor meetings
Speaker: Andrew Hall, Chief Executive Officer at IMV Inc.
Date: September 12, 2022
Time: 2:30 p.m. ET

Please contact your H.C. Wainwright representative for more information.

• Cantor Fitzgerald’s Oncology & HemOnc Conference, New York City
Format: Panel "Building I/O combinations: What are the Novel Ideas?" and one-on-one investor meetings
Speaker: Jeremy Graff, Ph.D., Chief Scientific Officer at IMV Inc.
Date: September 28, 2022
Time: 10:40 a.m. ET

On September 1, 2022 PTC Therapeutics, Inc. (NASDAQ: PTCT) reported that the company will present a company overview at the following conferences (Press release, PTC Therapeutics, SEP 1, 2022, View Source [SID1234618892]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Wells Fargo 17th Annual Healthcare Conference
Thursday, Sept. 8, at 1:55 p.m. EDT

Morgan Stanley 20th Annual Global Healthcare Conference
Monday, Sept. 12, at 4:15 p.m. EDT

The presentation will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics’ website at View Source and will be archived for 30 days following the presentation. It is recommended that users connect to PTC’s website several minutes prior to the start of the webcast to ensure a timely connection.

On September 1, 2022 Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported that Matt Pauls, Chair and CEO, Savara will present at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 (Press release, Savara, SEP 1, 2022, View Source [SID1234618909]). A webcast of the presentation will be available at 7:00 AM ET/4:00 AM PT on September 12, 2022 on Savara’s website at www.savarapharma.com/investors/events-presentations/ and archived for 90 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On September 1, 2022 SkylineDx, a leading molecular diagnostics company, reported the commercial launch of Merlin Assay as CE-IVD distributable test kit in Europe (Press release, SkylineDx, SEP 1, 2022, View Source [SID1234618925]). Merlin Assay identifies melanoma (skin cancer) patients that have a low risk for nodal metastasis and therefore can safely forgo a sentinel lymph node biopsy (SLNB) surgery . This is an invasive surgical procedure used to determine metastatic spread of the cancer for staging purposes. In approximately 80% of surgeries, the biopsy comes back negative for metastasis, where it does not further impact the patient pathway. The test provides a more personalized insight on the metastatic propensity of the tumor, identifying patients with a low-risk tumor that could avoid the surgery [2]. The CE-IVD device is based on a well-established qPCR method that can easily run in molecular diagnostic laboratories.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This news follows the company’s recent announcement of having obtained Medicare coverage for Merlin Assay’s counterpart in the United States, Merlin Test, serviced centrally from SkylineDx’s CAP/CLIA laboratory in San Diego (CA) [3]. The company is expanding its dermatology franchise’s geographical footprint with commercial activities in the key markets United States and Europe. Whilst Merlin Test and Merlin Assay are their first and lead products in dermatology, successive introductions of additional dermatology tests are anticipated [4].

As jointly announced in April 2021, Biocartis Group NV will act as SkylineDx’s commercial distribution partner for the European market [5].

"Launching Merlin Assay as CE-IVD marked manual kit in Europe signifies a major milestone in making our diagnostic solutions available to patients globally," comments Dharminder Chahal, CEO SkylineDx. "We are looking forward to enter this new phase of our partnership with Biocartis."

"We are very excited to start commercialization in Europe of SkylineDx’s CE-IVD marked manual kit of the Merlin Assay. In Europe we have long-standing relationships with our customer base of labs and hospitals. This very innovative Merlin Assay will now allow our customers to improve outcomes for melanoma patients," concludes Herman Verrelst, CEO Biocartis.

About Merlin Assay

Merlin Assay uses the CP-GEP model, a powerful proprietary algorithm that calculates the risk of metastasis in a patient’s sentinel lymph nodes [2]. The model is able to calculate risk on an individual basis through a combination analysis of 8 genes from the patient’s primary tumor, the tumor thickness and the patient’s age; and has been analytically and clinically validated. Further clinical research and validation studies on the predictive use of the CP-GEP model is the main focus of Merlin Study Initiative, developed under the wings of Falcon R&D Program. More information (including references) may be obtained at www.falconprogram.com. Merlin Assay’s US counterpart, Merlin Test, is commercially available and Medicare reimbursed as a Laboratory Developed Test serviced from SkylineDx’s CAP/CLIA laboratory in San Diego (CA).